Edwards Lifesciences Faces A Tougher Comparison As Street Bets On TMTT Momentum Holding

Edwards Lifesciences enters its third-quarter report with a quieter growth rate and a louder story. Revenue growth is expected to slow sharply from the 12.5% pace of the second quarter. Management has spent months warning that the strong back half of 2025 would make this year's comparisons look softer. The question is whether investors accept the deceleration as arithmetic or start to read it as fatigue in the core valve franchise.

Wall Street expects earnings of $0.73 per share on revenue of about $1.68 billion when Edwards reports after the close on November 4. That works out to growth of roughly 9% on the bottom line and 8.2% on the top line. Both are solid figures, but they fall short of the double-digit gains investors have grown used to. The Earnings Whisper sits at $0.76, modestly above consensus. That suggests the informal bar is a bit higher than the published one, which is typical for a company that has beaten and raised repeatedly. On the full year, management reaffirmed EPS guidance of $2.95 to $3.05, and consensus sits right at the $3.00 midpoint. Revenue is a different story. The guidance range was narrowed to $6.67 billion to $6.74 billion, yet the Street is parked at the very top of it. Analysts are effectively assuming Edwards finishes the year at its most optimistic outcome, so a quarter that merely lands in line could feel like a step back.

The most important evidence will come from transcatheter mitral and tricuspid therapies. TMTT sales rose about 45% in the second quarter to nearly $196 million, helped by what management described as an inflection in Evoque alongside strength in Pascal and Sapien M3. Hitting the raised $760 million to $780 million target requires roughly $195 million to $205 million per quarter in the second half. In other words, TMTT needs to hold or modestly build on second-quarter levels despite normal summer seasonality. A sequential dip would challenge the inflection narrative. A print at or above $200 million would validate it and lend credibility to the upcoming Pascal tricuspid approval and Sapien M3 rollout.

TAVR, still the bulk of the business, carries a guide of 8% to 9% growth after three consecutive raises. Investors will want growth to stay within that band and remain balanced between the U.S. and international markets. They will also want commentary on how the final TAVR coverage decision, expected in September, affects asymptomatic patient referrals. Early color on the Sapien X4S program, the ECLIPTIS appendage closure launch and the PROGRESS moderate aortic stenosis data at TCT would help frame the investor conference on December 4, where 2027 guidance is due.

The margin side is where the risks reside. Last quarter, top-line strength was absorbed by a tax rate now headed to the high end of 16% to 19%. Gross margin is also tracking toward the low end of 78% to 79% as currency swung to a roughly $35 million second-half headwind. Operating margin guidance at the high end of 28% to 29% is the offset to watch. This is also the first full quarter of reporting under new CFO Doretta Mistras, so consistency in messaging matters.

Sentiment has cooled, slipping from mildly bullish before the last report to mildly bearish now. The stock has risen 2.9% since July, trailing the S&P 500 slightly. At $90.56, it trades comfortably above its 200-day average of $85.25 and in the upper part of its post-earnings range. It sits a few percent below the $93.91 high. The setup is not euphoric, which leaves room for a constructive reaction. Ultimately, the narrative stays intact if TMTT proves its inflection was durable and TAVR holds its guide, giving Edwards the cushion to defend a revenue consensus already pinned to the top of its range.

This earnings preview was originally published on Earnings Whispers.

This article is for informational purposes only and is not investment advice. Earnings Whispers and its staff may hold positions in the securities mentioned. It is AI-assisted, based on proprietary Earnings Whispers data and company reports, and edited by Earnings Whispers staff.